Study will be the first clinical trial testing an investigational stem cell therapy aimed at restoring lost brain cells called neurons in people with advanced Parkinson’s disease (PD).

In a recent study, Memorial Sloan Kettering scientists used stem-cell engineering to repair brain injuries in rats. The results raise hope for future therapies that could prevent or fix nerve damage in cancer patients who need brain radiation.

Investigators have created the first-ever genetically engineered model of cancer made from human embryonic stem cells in culture.

Two Memorial Sloan Kettering physician-scientists were elected to one of the nation’s oldest and most respected medical honor societies.

Research at Memorial Sloan Kettering will benefit from renewed support for The Starr Cancer Consortium and the Tri-Institutional Stem Cell Initiative totaling $105 million.

A new center at the Sloan Kettering Institute is exploring the potential of embryonic stem cells and human adult cells to produce regenerative treatments and provide insights into cancer.

Memorial Sloan Kettering Cancer Center researchers have published new findings that may help explain why brain tumors called glioblastomas are so resistant to treatment.

Memorial Sloan Kettering researchers have engineered stem cells from patients with familial dysautonomia, a rare genetic disorder, and used them to explore the causes of the disease and to test drugs that might be effective against it.

Research led by investigators at Memorial Sloan Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.